HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $198
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on BioNTech (NASDAQ:BNTX) but lowers the price target from $210 to $198.
May 23, 2023 | 10:13 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on BioNTech (BNTX) but lowers the price target from $210 to $198.
The news of HC Wainwright & Co. maintaining a Buy rating on BioNTech (BNTX) is positive for the stock. However, the lowering of the price target from $210 to $198 may create some uncertainty among investors, potentially offsetting the positive impact of the Buy rating. Therefore, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100